128 related articles for article (PubMed ID: 35337966)
1. Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model.
Funk F; Weber K; Nyffenegger N; Fuchs JA; Barton A
Eur J Pharm Biopharm; 2022 May; 174():56-76. PubMed ID: 35337966
[TBL] [Abstract][Full Text] [Related]
2. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Funk F; Flühmann B; Barton AE
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
[TBL] [Abstract][Full Text] [Related]
3. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
4. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
5. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Pollock RF; Muduma G
Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.
Toblli JE; Cao G; Rico L; Angerosa M
Drug Des Devel Ther; 2017; 11():3401-3412. PubMed ID: 29238166
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
9. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
10. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
11. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
[TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.
Garbowski MW; Bansal S; Porter JB; Mori C; Burckhardt S; Hider RC
Haematologica; 2021 Nov; 106(11):2885-2896. PubMed ID: 33054113
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
Neiser S; Koskenkorva TS; Schwarz K; Wilhelm M; Burckhardt S
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455240
[TBL] [Abstract][Full Text] [Related]
15. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Funk F; Ryle P; Canclini C; Neiser S; Geisser P
Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
[TBL] [Abstract][Full Text] [Related]
16. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
17. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
19. Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Des Devel Ther; 2017; 11():2251-2263. PubMed ID: 28814833
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Connor JR; Zhang X; Nixon AM; Webb B; Perno JR
PLoS One; 2015; 10(5):e0125272. PubMed ID: 25973894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
